FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2896648752> ?p ?o ?g. }

• W2896648752 endingPage "47" @default.
• W2896648752 startingPage "38" @default.
• W2896648752 abstract "Zika virus (ZIKV) is a human-pathogenic flavivirus that has recently emerged as a global public health threat. ZIKV infection may be associated with congenital malformations in infected fetuses and severe neurological and systemic complications in infected adults. There are currently limited treatment options for ZIKV infection. AR-12 (OSU-03012) is a celecoxib derivative cellular kinase inhibitor that has broad-spectrum antiviral activities. In this study, we investigated the antiviral activity and mechanism of AR-12 against ZIKV. We evaluated the in vitro anti-ZIKV activity of AR-12, using cell protection and virus yield reduction assays, in multiple clinically relevant cell lines, and the in vivo treatment effects of AR-12 in a lethal mouse model using type I interferon receptor-deficient A129 mice. AR-12 inhibited ZIKV strains belonging to both the African and Asian/American lineages in Huh-7 and/or neuronal cells. AR12's IC50 against ZIKV was consistently <2 μM in these cells. ZIKV-infected A129 mice treated with intraperitoneally or orally administered AR-12 had significantly higher survival rate (50.0%–83.3% vs 0%, P < 0.05), less body weight loss, and lower blood and tissue ZIKV RNA loads than untreated control A129 mice. These anti-ZIKV effects were likely the results of down-regulation of the PI3K/Akt pathway by AR-12. Clinical trials using the clinically available and broad-spectrum AR-12 as an empirical treatment should be considered especially for patients residing in or returning from areas endemic of ZIKV and other arboviral infections who present with an acute undifferentiated febrile illness." @default.
• W2896648752 created "2018-10-26" @default.
• W2896648752 creator A5014473034 @default.
• W2896648752 creator A5028446710 @default.
• W2896648752 creator A5028624613 @default.
• W2896648752 creator A5030565867 @default.
• W2896648752 creator A5039646483 @default.
• W2896648752 creator A5040481654 @default.
• W2896648752 creator A5042094591 @default.
• W2896648752 creator A5042502894 @default.
• W2896648752 creator A5043511757 @default.
• W2896648752 creator A5043656890 @default.
• W2896648752 creator A5053362671 @default.
• W2896648752 creator A5054256455 @default.
• W2896648752 creator A5057504466 @default.
• W2896648752 creator A5088018354 @default.
• W2896648752 creator A5091484483 @default.
• W2896648752 date "2018-12-01" @default.
• W2896648752 modified "2023-10-13" @default.
• W2896648752 title "The celecoxib derivative kinase inhibitor AR-12 (OSU-03012) inhibits Zika virus via down-regulation of the PI3K/Akt pathway and protects Zika virus-infected A129 mice: A host-targeting treatment strategy" @default.
• W2896648752 cites W1947409115 @default.
• W2896648752 cites W1964940884 @default.
• W2896648752 cites W1975120587 @default.
• W2896648752 cites W1980143030 @default.
• W2896648752 cites W1995570500 @default.
• W2896648752 cites W2008370957 @default.
• W2896648752 cites W2011706334 @default.
• W2896648752 cites W2017248106 @default.
• W2896648752 cites W2026178330 @default.
• W2896648752 cites W2036943232 @default.
• W2896648752 cites W2038601283 @default.
• W2896648752 cites W2041802815 @default.
• W2896648752 cites W2085605782 @default.
• W2896648752 cites W2093964315 @default.
• W2896648752 cites W2097580944 @default.
• W2896648752 cites W2110925738 @default.
• W2896648752 cites W2115555188 @default.
• W2896648752 cites W2153521646 @default.
• W2896648752 cites W2166091310 @default.
• W2896648752 cites W2177206102 @default.
• W2896648752 cites W2229955013 @default.
• W2896648752 cites W2255243349 @default.
• W2896648752 cites W2290442748 @default.
• W2896648752 cites W2297563545 @default.
• W2896648752 cites W2299248163 @default.
• W2896648752 cites W2316873028 @default.
• W2896648752 cites W232286354 @default.
• W2896648752 cites W2345638947 @default.
• W2896648752 cites W2508596867 @default.
• W2896648752 cites W2521079522 @default.
• W2896648752 cites W2522400009 @default.
• W2896648752 cites W2526467390 @default.
• W2896648752 cites W2549922333 @default.
• W2896648752 cites W2552113437 @default.
• W2896648752 cites W2552845139 @default.
• W2896648752 cites W2576816878 @default.
• W2896648752 cites W2587514484 @default.
• W2896648752 cites W2587777516 @default.
• W2896648752 cites W2591060052 @default.
• W2896648752 cites W2728862060 @default.
• W2896648752 cites W2735493269 @default.
• W2896648752 cites W2739084511 @default.
• W2896648752 cites W2749489275 @default.
• W2896648752 cites W2771181960 @default.
• W2896648752 cites W2795335509 @default.
• W2896648752 cites W2800485840 @default.
• W2896648752 cites W4210967474 @default.
• W2896648752 doi "https://doi.org/10.1016/j.antiviral.2018.10.007" @default.
• W2896648752 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7113887" @default.
• W2896648752 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30326204" @default.
• W2896648752 hasPublicationYear "2018" @default.
• W2896648752 type Work @default.
• W2896648752 sameAs 2896648752 @default.
• W2896648752 citedByCount "34" @default.
• W2896648752 countsByYear W28966487522019 @default.
• W2896648752 countsByYear W28966487522020 @default.
• W2896648752 countsByYear W28966487522021 @default.
• W2896648752 countsByYear W28966487522022 @default.
• W2896648752 countsByYear W28966487522023 @default.
• W2896648752 crossrefType "journal-article" @default.
• W2896648752 hasAuthorship W2896648752A5014473034 @default.
• W2896648752 hasAuthorship W2896648752A5028446710 @default.
• W2896648752 hasAuthorship W2896648752A5028624613 @default.
• W2896648752 hasAuthorship W2896648752A5030565867 @default.
• W2896648752 hasAuthorship W2896648752A5039646483 @default.
• W2896648752 hasAuthorship W2896648752A5040481654 @default.
• W2896648752 hasAuthorship W2896648752A5042094591 @default.
• W2896648752 hasAuthorship W2896648752A5042502894 @default.
• W2896648752 hasAuthorship W2896648752A5043511757 @default.
• W2896648752 hasAuthorship W2896648752A5043656890 @default.
• W2896648752 hasAuthorship W2896648752A5053362671 @default.
• W2896648752 hasAuthorship W2896648752A5054256455 @default.
• W2896648752 hasAuthorship W2896648752A5057504466 @default.
• W2896648752 hasAuthorship W2896648752A5088018354 @default.
• W2896648752 hasAuthorship W2896648752A5091484483 @default.
• W2896648752 hasBestOaLocation W28966487521 @default.
• W2896648752 hasConcept C159047783 @default.
• W2896648752 hasConcept C190283241 @default.

• next